Otmane Nafidi, Denis Marleau, André Roy, Marc Bilodeau – 27 August 2010 – We currently face the more widespread use of marginal livers for organ transplantation. Therefore, it is imperative to adequately identify the factors affecting early and late graft survival in that setting. The objective of this study was to determine the donor variables associated with graft survival in the liver transplant program of the University of Montreal. We retrospectively studied the survival of 634 grafts transplanted into 634 recipients between 1990 and 2008.

Cindy Ka Yee Cheung, Chung Mau Lo, Kwan Man, George Ka Kit Lau – 27 August 2010 – Liver grafts from donors positive for antibody to hepatitis B core antigen (anti‐HBc) may be used for transplantation in patients with hepatitis B virus (HBV)–related liver disease, and an occult HBV infection may develop from either source. Liver biopsy was performed for 31 patients who remained seronegative for hepatitis B surface antigen for a median of 44.5 months (range = 13.6‐126.4 months) and received nucleoside analogue prophylaxis post‐transplant.

Christopher L. Bowlus, Chin‐Shang Li, Tom H. Karlsen, Benedicte A. Lie, Carlo Selmi – 27 August 2010 – Primary sclerosing cholangitis (PSC) is well characterized in European populations. We aimed to characterize clinical characteristics and human leukocyte antigen (HLA) associations in a population of European American, Hispanic, and African American PSC patients listed for liver transplantation (LT).

Federico Salamone, Fabio Galvano, Giovanni Li Volti – 26 August 2010

Katrina J. Allen, Nadine A. Bertalli, Nicholas J. Osborne, Clare C. Constantine, Martin B. Delatycki, Amy E. Nisselle, Amanda J. Nicoll, Dorota M. Gertig, Christine E. McLaren, Graham G. Giles, John L. Hopper, Gregory J. Anderson, John K. Olynyk, Lawrie W. Powell, Lyle C.

Stephen A. Harrison, Lorenzo Rossaro, Ke‐Qin Hu, Keyur Patel, Hans Tillmann, Sandeep Dhaliwal, Dawn M. Torres, Kenneth Koury, Venkata S. Goteti, Stephanie Noviello, Clifford A. Brass, Janice K. Albrecht, John G. McHutchison, Mark S. Sulkowski – 26 August 2010 – Elevated low‐density lipoprotein (LDL) levels and statin use have been associated with higher sustained virological response (SVR) rates in patients receiving chronic hepatitis C therapy. However, these relationships have not been well characterized in randomized controlled trials.

Darmendra Ramcharran, Abdus S. Wahed, Hari S. Conjeevaram, Rhobert W. Evans, Tianyi Wang, Steven H. Belle, Leland J. Yee, for the Virahep‐C Study Group – 26 August 2010 – Approximately one half of patients who undergo antiviral therapy for chronic hepatitis C virus (HCV) genotype 1 infection do not respond to treatment. African Americans (AAs) are less responsive to treatment than Caucasian Americans (CAs), but the reasons for this disparity are largely unknown. Recent studies suggest that serum lipids may be associated with treatment response.

Rohit Kohli, Michelle Kirby, Stavra A. Xanthakos, Samir Softic, Ariel E. Feldstein, Vijay Saxena, Peter H. Tang, Lili Miles, Michael V. Miles, William F. Balistreri, Stephen C. Woods, Randy J. Seeley – 26 August 2010 – Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans.

Xu‐Feng Zhang, Xinping Tan, Gang Zeng, Amalea Misse, Sucha Singh, Youngsoo Kim, James E. Klaunig, Satdarshan P. S. Monga – 26 August 2010 – Activation of β‐catenin, the central effector of the canonical Wnt pathway and a recognized oncogene, has been implicated in hepatocellular carcinoma. We examined N‐nitrosodiethylamine (DEN)‐induced tumorigenesis in hepatic β‐catenin conditional knockout mice (β‐cat KO). Male β‐cat KO and age‐ and sex‐matched littermate controls were given a single intraperitoneal DEN injection and followed for 6‐12 months for hepatic tumors.

Yavuz Beyazit, Murat Kekilli, Tugrul Purnak, Mevlut Kurt – 26 August 2010